

# Potentially inappropriate prescribing to the elderly: comparison of new protocol to Beers criteria with relation to hospitalizations for ADRs

---

**Matanović, Suzana Mimica; Vlahović-Palčevski, Vera**

*Source / Izvornik:* **European Journal of Clinical Pharmacology, 2014, 70, 483 - 490**

**Journal article, Published version**

**Rad u časopisu, Objavljena verzija rada (izdavačev PDF)**

<https://doi.org/10.1007/s00228-014-1648-3>

*Permanent link / Trajna poveznica:* <https://um.nsk.hr/um:nbn:hr:184:263783>

*Rights / Prava:* [Attribution-NonCommercial-NoDerivs 3.0 Unported / Imenovanje-Nekomercijalno-Bez prerađivanja 3.0](#)

*Download date / Datum preuzimanja:* **2024-11-03**



*Repository / Repozitorij:*

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



# Potentially inappropriate prescribing to the elderly: comparison of new protocol to Beers criteria with relation to hospitalizations for ADRs

Suzana Mimica Matanović · Vera Vlahović-Palčevski

Received: 17 October 2013 / Accepted: 10 January 2014 / Published online: 24 January 2014  
© Springer-Verlag Berlin Heidelberg 2014

## Abstract

**Purpose** Screening tools for detecting potentially inappropriate medications (PIMs) represent an important way to assess drug prescribing in the elderly. Recently, we introduced a new comprehensive tool to detect both PIMs and clinically important drug-drug interactions (DDI). The aim of the study was to assess the applicability of the new tool.

**Methods** The new tool was used to detect PIMs and DDI and to assess their relation to morbidity and hospital admissions. It was also compared to the widely used Beers criteria. The study population included 454 consecutive patients aged  $\geq 65$  years who were acutely admitted to the Department of Internal Medicine of the University Hospital of Osijek. The Naranjo protocol was used to analyze the causal relationship between a drug and an adverse event.

**Results** According to the new protocol, 44 % patients were taking PIMs, while 33 % patients were taking drugs with potentially serious DDIs. In 11 % of the overall number of patients, the cause of admission was adverse drug reaction (ADR), and among contributing drugs, 44 % were potentially inappropriate according to our protocol. Gastrointestinal bleeding was the most common diagnosis causing ADR-associated admission, and in 72 % cases, either PIM or a potentially serious DDI was involved.

**Conclusion** The new Croatian tool detected a high number of patients taking PIMs and/or having potentially important drug-drug interactions. The tool also detected almost half of the drugs contributing to ADR-associated admission. We expect the tool to be useful in prescription evaluation for the elderly inpatient and outpatient population.

**Keywords** Elderly patients · PIM screening tools · Potentially inappropriate medications · Drug–drug interactions · Adverse drug reactions

## Introduction

In recent years, geriatric pharmacotherapy has come into focus because the elderly consume most of the health care resources due to their rapidly growing numbers, especially in developed countries [1, 2]. The elderly are at an increased risk of adverse drug reactions (ADRs) as a result of co-morbidities, polypharmacy, and age-related changes in the pharmacodynamics and pharmacokinetics of drugs [3–7].

Potentially inappropriate medications (PIMs) may pose more risks than benefits to a patient, particularly where safer alternative therapies exist for the same condition. Therefore, avoiding PIMs represents a strategy aimed at reducing drug-related mortality and morbidity [8–12].

Several screening tools for the detection of PIMs have been published, the most frequently cited being Beers criteria, developed in the United States. The first version of Beers criteria was published in 1991, with updates in 1993, 2003, and the recent update in April 2012 [13–17]. The recent update has brought major changes in the list of potentially inappropriate drugs. The applicability of Beers criteria to elderly patients in Europe is not straightforward, as many drugs from the Beers list are still unavailable in European countries. Also, some of the Beers criteria are controversial (e.g., amiodarone) and the duplication of treatments or drug-drug interactions are not addressed. Recently, we introduced a new comprehensive tool detecting both PIMs and clinically important drug-drug interactions [18]. The new tool detects PIMs by adapting previously adopted tools: the adjusted 2003 version of Beers criteria (2003 version was used because it was available when our protocol was developed in 2008), the

S. M. Matanović (✉)  
University hospital Osijek, Huttlerova 4, 31000 Osijek, Croatia  
e-mail: mimica-matanovic.suzana@kbo.hr

V. Vlahović-Palčevski  
University Hospital Rijeka, Krešimirova 42, 51000 Rijeka, Croatia

French consensus panel, McLeod's list, and Lindblad's list of clinically important drug-disease interactions [19–21]. We assumed that combining PIMs and potential drug-drug interactions in the same protocol would enable a more thorough assessment of drug prescribing in the elderly. Thus, we used Hanlon's and Malone's lists of drug-drug interactions in the elderly and expanded them with four more clinically relevant potential drug-drug interactions [18, 22, 23].

As the application of our tool in both detecting and assessing PIM- or drug interaction-related morbidity and hospital admissions had to be tested in a real-life environment, we compared our tool with the new Beers criteria and in relation to hospitalizations for ADRs. The study population included acutely ill elderly patients admitted to the department of internal medicine of a university hospital.

## Methods

We prospectively analyzed 454 consecutive patients aged 65 years or more who were acutely admitted to the Department of Internal Medicine of the University Hospital of Osijek during two periods: August–October 2009 and January–April 2010. For each patient, we collected data on drug consumption before admission and during hospital stay: data on types and dosages of all drugs, including OTC drugs and herbal supplements were collected. Drug consumption before admission was referred to all medications that the patient was taking regularly for at least 2 weeks before admission to the hospital, but long-term use of NSAIDs or stimulant laxatives was defined as at least 3 months of continuous use. Data on drugs were obtained by interviewing the patient and were retrieved from medical records and the patient's family physician. Data on the condition or disease causing hospital admission, comorbidities, serum creatinine values, body weight and history of ADRs were also recorded. Estimation of glomerular filtration rate was calculated using the Cockcroft-Gault formula. Patients that were electively admitted (i.e., patients that were admitted for diagnostic evaluation of their condition, where the date of admission was known in advance) were not included.

Potentially inappropriate medicines were analyzed using both our new screening tool and the 2012 Beers criteria [15, 16, 18]. According to our screening tool, we also assessed potentially serious drug-drug interactions.

Among causes of hospital admission, we evaluated those that were likely to be caused by ADRs. The causal relationship between a drug and an adverse event was analyzed using the Naranjo protocol [24]. A trained specialist in clinical pharmacology performed all the Naranjo scoring. As defined by the Naranjo protocol, with scores in the range of 5–8, the relationship was considered probable, while with a score of 9 or more, it was considered definite. Co-morbidity was calculated

using both the basic and age-adjusted Charlson co-morbidity index [25].

The aim of the study was to determine: (1) the number of PIMs using two different tools, (2) the frequency of prescribing drugs with potentially serious drug-drug interactions (two drugs in a possible interaction were calculated as a case of one interaction), (3) the frequency of hospital admission caused by ADRs, and (4) the importance of PIMs in those ADRs. We also assessed the difference in the number of drugs in female and male patients, and also in the number of drugs in groups of patients with or without PIMs. Differences regarding age, sex, co-morbidity, renal function (as a percentage of patients with estimated GF <60 ml/min), history of ADRs, and the number of drugs in groups of patients that were admitted for ADRs or other causes were assessed. In NSAIDs users with or without GI bleeding, the consumption of proton pump inhibitors (PPI) was analyzed.

The study received approval by both ethics committees of the University Hospital of Osijek and the Medical Faculty of Osijek.

## Statistical analysis

IBM SPSS Statistics 19 software was used to analyze the data. Comparison of the categorical variables was performed using the  $\chi^2$  test or Fisher's exact test, and a comparison of the continuous variables was performed using the *t*-test or the Mann–Whitney test, depending whether the data were normally distributed or not. The Kolmogorov–Smirnov test was used to test the normality of data distribution. While comparing continuous variables in the same patients before and during hospitalization, we used the *t*-test for dependent samples and the Wilcoxon rank-sum test.

Sample size was calculated using GPower software: with 0.05 significance level, 99 % power and large effect size, we calculated that the minimum number of subjects would be 238 (we included more than the minimum number of subjects).

$P < 0.05$  was selected as level of statistical significance.

## Results

Characteristics of the study population are shown in Table 1. Sociodemographic data, data on drug consumption, and clinical data are included.

The mean number of drugs (SD) before admission and during hospital stay was 5.3 (2.9) and 6.1 (2.9), respectively ( $p < 0.001$ ). Women were found to be taking significantly more drugs compared to men (5.6 (2.8)) and 4.8 (3.0), respectively,  $p = 0.0053$ ).

**Table 1** Study population characteristics

|   | Number of patients<br>(percentage of all patients) |
|---|--|
| <b>Sociodemographic characteristics</b>             |  |
| Female sex  | 262 (57.7)   |
| Male sex  | 192 (42.3)   |
| Age, y  |  |
| 65–74   | 232 (51.1)   |
| 75–84   | 198 (43.6)   |
| ≥85   | 24 (5.3)   |
| <b>Drug-related characteristics</b>                 |  |
| Number of drugs used before admission               |  |
| ≤4  | 193 (42.5)   |
| ≥5  | 262 (57.5)   |
| ≥9  | 70 (15.4)  |
| Use of cardiovascular system drugs<br>(ATC class C) | 378 (83.3)   |
| Use of ACE inhibitors or ATII blockers              | 264 (58.2)   |
| Use of nervous system drugs<br>(ATC class N)        | 243 (53.5)   |
| Use of benzodiazepines                              | 144 (31.7)   |
| Use of NSAIDs                                       | 103 (22.7)   |
| <b>Clinical characteristics</b>                     |  |
| Diagnoses leading to admission                      |  |
| Ischaemic heart disease                             | 106 (23.3)   |
| Congestive heart failure                            | 79 (17.4)  |
| Acute upper gastrointestinal bleeding               | 52 (11.5)  |
| Heart conduction disorder                           | 44 (9.7)   |
| Poorly controlled diabetes mellitus                 | 27 (6.0)   |
| Co-morbidities                                      |  |
| Hypertension  | 220 (48.5)   |
| Ischaemic heart disease                             | 168 (37.0)   |
| Congestive heart failure                            | 137 (30.2)   |
| Diabetes mellitus                                   | 131 (28.8)   |
| Peptic ulcer disease                                | 40 (8.8)   |

### Potentially inappropriate medications

As identified by the new protocol, 200 patients (44.1 %) were exposed to a total of 274 PIMs. Among those, 141 patients (31.1 %) were taking one PIM, 44 (9.7 %) patients were taking two PIMs, and 15 patients (3.3 %) had been prescribed three PIMs. The mean number of drugs (SD) in the group of patients taking PIMs was significantly higher as compared to patients not taking PIMs (6.3 (2.7) and 4.5 (2.8), respectively ( $p < 0.001$ )).

The most common PIMs detected by the new protocol were: inappropriate use of NSAIDs (63 times); long-acting benzodiazepines (63 times); amiodarone (47 times), cerebral vasodilators (25 times), and drugs with anticholinergic properties (22 times). All identified PIMs are presented in Table 2.

The new 2012 version of Beers criteria identified a total of 409 PIMs, taken by 263 patients (57.9 %). The most common of them were: non-COX-selective NSAIDs (103), short- and intermediate-acting benzodiazepines (99), and amiodarone (47) (see Table 2.).

### Adverse drug reaction-related hospitalizations

ADRs were considered to be cause of admission only in patients meeting a Naranjo score  $\geq 5$ , i.e., the relationship between the drug and reactions was concluded as probable or definite in those cases. The mean (SD) Naranjo score was 6.9 (0.9) and the highest score was 8 (i.e., there was no case of definite relationship, as there were no re-challenge cases).

Among the 454 patients, in 50 of these ADRs were identified as a cause of admission (11.0 %) (Table 3). PIMs identified by the new protocol contributed to 44 % cases of ADR-related admissions, whereas those identified by 2012 Beers list contributed to 54 % cases of such admissions, respectively.

Half of all ADR-related hospital admissions (25 patients) were attributed to drug-induced upper gastrointestinal (GI) bleeding. Among them, five cases of bleeding were caused by aspirin and 20 cases by NSAIDs. The new protocol identified 64 % of all drug-induced cases of upper GI bleeding, whereas the Beers list identified 88 % of such cases. In our study, NSAID users without upper GI bleeding did not take significantly more proton pump inhibitors (PPIs), as compared to NSAIDs users that were admitted for upper GI bleeding (10.0 % vs 10.8 %, respectively,  $p = 1.000$ ).

"Appropriate drugs" were also involved in admission. All admissions caused by warfarine overdose, bradycardia, and hypotension were associated with the use of appropriate drugs (i.e., warfarine, beta blockers (bisoprolol and carvedilol) and ACE inhibitors (lisinopril+hydrochlorothiazide)). Among six patients who were admitted for hypoglycaemia, three of them were using potentially inappropriate glibenclamide, while the other three (appropriate) drugs included insulin, glimepiride, and gliclazide.

Patients that presented with ADRs were more likely to be prescribed inappropriate medications compared to patients without ADRs (64.0 % vs 40.4 % respectively). They were also more likely to be prescribed NSAIDs (46.0 % vs 20.8 % respectively) and warfarine (26.0 % vs 6.9 % respectively).

Patients admitted for ADRs, when compared to those admitted for other diagnoses, did not differ statistically in terms of age ( $75.6 \pm 6.1$  vs  $74.0 \pm 5.9$ , respectively), sex (58.0 % vs 57.7 %, respectively), number of drugs taken before admission ( $4.7 \pm 2.3$  vs  $5.4 \pm 3.0$ , respectively), co-morbidity (expressed as basic or age-adjusted Charlson co-morbidity index:  $2.0 \pm 1.5$  and  $2.1 \pm 1.5$ , respectively, and  $5.2 \pm 1.8$  and  $5.0 \pm 1.6$ , respectively), renal function impairment (50.0 % vs 51.2 %, respectively, expressed as the percentage of patients

**Table 2** Potentially inappropriate medications identified by the new protocol and the 2012 Beers criteria

| New protocol  |   | 2012 Beers criteria  |   |
|---|---|--|---|
| Type of medication  | Number of drugs, N=274 (percentage of all PIMs) | Type of medication   | Number of drugs, N=409 (percentage of all PIMs) |
| Drugs with unfavourable benefit/risk ratio                                    |   | Drugs to be avoided independent of diagnoses or conditions |   |
| Analgesics  |   | Pain   |   |
| Indomethacin  | 5 (1.8)   | Indomethacin   | 5 (1.2)   |
| Concomitant use of two or more NSAIDs   | 4 (1.5)   | Non-COX-selective NSAIDs, oral                             | 103 (25.2)                                      |
| Long-term use of full-dosage, longer half-life NSAIDs: piroxicam <sup>a</sup> | 12 (4.3)  |  |   |
| Drugs with anticholinergic properties   |   | Central nervous system                                     |   |
| Amitriptyline   | 4 (1.5)   | Tertiary TCAs - amitriptyline                              | 4 (1.0)   |
| Maprotiline   | 1 (0.4)   | Antipsychotics – first and second generation               | 17 (4.2)  |
| Fluphenazine  | 2 (0.7)   |  |   |
| Promazine   | 10 (3.6)  |  |   |
| Biperiden   | 3 (1.1)   |  |   |
| Sedative or hypnotic drugs  |   |  |   |
| Long-acting benzodiazepines   |   | Benzodiazepines  |   |
| Diazepam  | 44 (16.1)                                       | Long-acting (diazepam, flurazepam)                         | 45 (11.0)                                       |
| Nitrazepam  | 12 (4.4)  |  |   |
| Flurazepam  | 1 (0.4)   |  |   |
| Bromazepam  | 6 (2.2)   | Short- and intermediate-acting                             | 99 (24.2)                                       |
| Meprobamat  | 4 (1.5)   | Meprobamat   | 4 (1.0)   |
|   |   | Nonbenzodiazepine hypnotics                                | 26 (6.4)  |
| Antihypertensives   |   |  |   |
| Centrally-acting: moxonidine  | 16 (5.8)  |  |   |
| Nifedipine, short-acting  | 2 (0.7)   | Cardiovascular   |   |
| Doxazosine  | 1 (0.4)   | Alpha <sub>1</sub> blockers – doxazosin                    | 1 (0.2)   |
| Antiarrhythmics   |   | Antiarrhythmic drugs                                       |   |
| Amiodarone  | 47 (17.2)                                       | amiodarone   | 47 (11.5)                                       |
|   |   | propafenone  | 7 (1.7)   |
| Drugs used to treat gastrointestinal disorders                                |   | Anticholinergics (excludes TCAs)                           |   |
| Scopolamine   | 2 (0.7)   | Antispasmodics - scopolamine                               | 2 (0.5)   |
| Long-term use of stimulant laxatives: bisacodyl <sup>b</sup>                  | 2 (0.7)   | Gastrointestinal   |   |
|   |   | Metoclopramide   | 8 (2.0)   |
| Long-acting sulfonyleureas  |   | Endocrine  |   |
| Glibenclamide   | 7 (2.6)   | Sulphonylureas, long duration - glibenclamide              | 7 (1.7)   |
| Other   |   | Anti-infective   |   |
| Nitrofurantoin  | 2 (0.7)   | Nitrofurantoin   | 2 (0.5)   |
| Drugs to be avoided with certain diseases/conditions                          |   | Drugs to be avoided considering disease or syndrome        |   |
| Heart failure – long-term prescription of NSAIDs <sup>a</sup>                 | 7 (2.6)   | Heart failure – NSAIDs                                     | 7 (1.7)   |
| Hypertension – long-term prescription of NSAIDs <sup>a</sup>                  | 16 (5.8)  |  |   |
| Chronic renal failure – long-term prescription of NSAIDs <sup>a</sup>         | 5 (1.8)   | Chronic kidney disease (stage IV,V) - NSAIDs               | 5 (1.2)   |
| Gastric or duodenal ulcers – NSAIDs   | 6 (2.2)   | History of gastric or duodenal ulcers – NSAIDs             | 6 (1.5)   |
| Gastric or duodenal ulcers – aspirin  | 2 (0.7)   | History of gastric or duodenal ulcers – aspirin            | 2 (0.5)   |
| Patients receiving anticoagulant therapy - NSAIDs                             | 1 (0.4)   |  |   |
| Patients receiving anticoagulant therapy – aspirin                            | 1 (0.4)   |  |   |
| COPD - long-acting benzodiazepines  | 5 (1.8)   |  |   |
| Osteoarthritis - long-term prescription of NSAIDs <sup>a</sup>                | 7 (2.6)   |  |   |
| Dementia - benzodiazepines  | 7 (2.6)   | Dementia or cognitive impairment -benzodiazepines          | 7 (1.7)   |



**Table 2** (continued)

| New protocol                         |   | 2012 Beers criteria                               |   |
|--------------------------------------|---|---|---|
| Type of medication                   | Number of drugs, <i>N</i> =274 (percentage of all PIMs) | Type of medication                                | Number of drugs, <i>N</i> =409 (percentage of all PIMs) |
| Dementia – conventional neuroleptics | 5 (1.8)   | Dementia or cognitive impairment - antipsychotics | 5 (1.2)   |
| Drugs with questionable efficacy     |   |   |   |
| Gingko-biloba                        | 9 (3.3)   |   |   |
| Pentoxifylline                       | 4 (1.5)   |   |   |
| Betahistine                          | 8 (2.9)   |   |   |
| Cinnarizine                          | 4 (1.5)   |   |   |

<sup>a</sup> long-term use of NSAIDs defined as continuous every day use for  $\geq 3$  months

<sup>b</sup> long-term use of stimulant laxatives defined as continuous every-day use for  $\geq 3$  months

with estimated glomerular filtration rate  $<60$  ml/min), or a positive history of adverse drug reactions (24.0 % vs. 14.9 %, respectively).

Individual drugs (as defined by the new protocol) that caused PIM-related hospital admissions are presented in Table 3. Diclofenac was associated with five cases of upper GI bleeding caused by PIMs.

#### Drug-drug interactions

A total of 149 patients (32.8 %) were found to be taking drugs with potentially serious drug-drug interactions, as defined by our protocol. Among those, 115 patients (25.3 %) had one potential drug-drug interaction, 21 (4.6 %) patients had two, 11 patients (2.4 %) had three and two patients (0.4 %) had four potentially serious drug-drug interactions. The most common potential drug-drug interactions were: interactions possibly resulting in hyperkalaemia, involving ACE inhibitors, ATII blockers, potassium-sparing diuretics or potassium supplements (56 times); interactions involving the inhibiting effects of amiodarone on other drugs, e.g., warfarine, atorvastatin/simvastatin or methylglucosin (36 times); interactions between two drugs with CNS depressing properties, e.g., benzodiazepines and opiate analgesics (31 times); and interactions involving two drugs with anticoagulant/antiplatelet activity (28 times).

Drug-drug interactions possibly contributed to two hospital admissions caused by warfarine overdose and seven caused by upper GI bleeding. Among the latter seven interactions, two were the sole reason for GI bleeding-related admission (interactions of aspirin with diclofenac or ibuprofen), while in the other five cases both PIMs and drug-drug interactions were present. By evaluating both PIMs and drug-drug interactions, our protocol was able to detect 18 among 25 cases of ADR-related GI bleeding.

#### Discussion

Our protocol identified PIMs in 44.1 % patients and the 2012 Beers criteria identified them in 57.9 % patients. The Beers list identifies entire classes of drugs as potentially inappropriate: all benzodiazepines (short- and long-acting), all new and older antipsychotics, and all non-selective NSAIDs. Our patients were taking those drug classes commonly (31.7 %, 22.7 %, and 5.0 % were taking benzodiazepines, non-selective NSAIDs, and antipsychotics, respectively), which resulted in high percentage of patients with PIMs, as measured by the new Beers criteria. Each drug listed as inappropriate according to the 2012 Beers criteria is not absolutely, but is relatively inappropriate in predefined conditions, which in turn makes straightforward comparison between the 2012 Beers and other explicit criteria difficult.

Including NSAIDs in the PIMs list is appreciated, and we advocated for that when developed our protocol. As confirmed by many studies, NSAIDs are commonly used by the elderly, mostly for chronic musculoskeletal pain [26, 27]. In our study, almost one-quarter of all patients reported taking NSAIDs regularly prior to hospital admission. Chronic pain syndromes in the elderly often necessitate permanent analgesics use, while this age group is particularly at a high risk for NSAID-related ADRs. Advanced age is an independent risk factor for NSAID-related GI toxicity, and when such toxicity occurs, the elderly are at a higher risk for serious complications, e.g., bleeding or perforation [28, 29]. Also, numerous studies have demonstrated the underutilization of gastroprotective drugs in elderly patients taking NSAIDs [30].

Now that high cardiovascular risk has been recognized as a consequence of selective cyclooxygenase-2 (COX-2) inhibitors use, non-selective NSAIDs have also come into focus for assumed prothrombotic effects and CV toxicity. It appears that NSAID-induced fluid retention and hypertension also contribute to CV adverse effects. There are meta-analyses showing an

**Table 3** Hospital admissions caused by adverse drug reactions (ADRs) and the role of PIMs

| Type of ADRs causing admission  | No. of patients with ADRs causing admission, <i>N</i> =50 (percentage of patients with ADRs causing admission) | PIMs causing ADRs, identified by the new protocol ( <i>N</i> =22) |  | No. of patients with PIMs causing ADRs, identified by 2012 Beers list <i>N</i> =27 (percentage of patients with ADRs causing admission) |
|---------------------------------|--|---|--|---|
|                                 |  | Type of potentially inappropriate medication                      | No. of patients (percentage of patients with ADRs causing admission) |   |
| Upper gastrointestinal bleeding | 25 (50)  | indomethacin  | 1 (2)  | 22 (44)   |
|                                 |  | piroxicam   | 2 (4)  |   |
|                                 |  | NSAIDs with PUD   | meloxicam 2 (4)  |   |
|                                 |  |   | ketoprofen 1 (2)   |   |
|                                 |  | aspirin with PUD  | aspirin 1 (2)  |   |
|                                 |  | long-term NSAIDs in osteoarthritis                                | diclofenac 1 (2)   |   |
|                                 |  | long-term NSAIDs in hypertension                                  | diclofenac 2 (4)   |   |
|                                 |  | long-term NSAIDs in heart failure                                 | ibuprofen 1 (2)  |   |
|                                 |  |   | diclofenac 1 (2)   |   |
|                                 |  | long-term NSAIDs in renal failure                                 | diclofenac 1 (2)   |   |
|                                 |  | NSAIDs in patients taking warfarin                                | diclofenac 1 (2)   |   |
|                                 |  | aspirin in patients taking warfarin                               | aspirin 1 (2)  |   |
|                                 |  | concomitant 2 NSAIDs  | piroxicam + meloxicam 1 (2)  |   |
|                                 |  | Warfarine overdose  | 10 (20)  |   |
| Hypoglycemia                    | 6 (12)   | glibenclamide   | 3 (6)  | 3 (6)   |
| Bradycardia                     | 3 (6)  | /   | 0  | 0   |
| Anaphylactic shock              | 2 (4)  | amiodarone  | 1 (2)  | 1 (2)   |
| Hypotension                     | 2 (4)  | /   | 0  | 0   |
| Bowel dysfunction               | 1 (2)  | bisacodyl   | 1 (2)  | 0   |
| Hyperthyreosis                  | 1 (2)  | amiodarone  | 1 (2)  | 1 (2)   |

increased risk for myocardial infarction and stroke with individual non-selective NSAID use. Risks for NSAID-related CV side effects include established CV disease or an estimated 10-year risk >20 % [31].

While some authors opt for the evaluation of GI and CV risk prior to NSAID use in the elderly, regulatory agencies, including the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) recommend using NSAIDs "in minimum effective dose[s] for the shortest possible duration". In October 2012, the EMA finished its new review on the cardiovascular risks of non-selective NSAIDs, concluding that "the overall benefit-risk balance of these medicines remained positive, but that a small increased cardiovascular risk could not be excluded"[32]. However, the guidelines of the American Geriatrics Society (AGS) for the management of persistent pain in older persons (published in 2009) are in concordance with our recommendations for appropriate analgesics use in the elderly [33]. According to the AGS guidelines, acetaminophen is recommended as an initial and ongoing pharmacotherapy in the treatment of persistent mild to moderate pain in the elderly, while all patients with moderate to severe pain should be considered for opioid

therapy. Nonselective NSAIDs and COX-2 selective inhibitors "may be considered rarely, and with extreme caution, in highly selected individuals".

Most studies show that ADRs cause approximately 5 % of hospital admission in general population, but the percentage rises to 10 % in the elderly, which is in concordance with our results [34–38]. In a similar Swedish retrospective study of 154 elderly patients admitted to the emergency department of a university hospital, the admission was drug-related in 14 % patients [39].

The only Croatian study on ADR-related admissions analyzed adult patients (regardless of their age) admitted to the department of internal medicine of a university hospital. The result show that 2.5 % of admissions were caused by ADRs. The difference between results in our two studies (i.e., 2.5 % vs 11 % of ADR-caused admissions) could be explained by the difference in age of the studied population and by different inclusion criteria for acute admission. The main cause for admission in both studies was upper gastrointestinal tract bleeding (64.6 % and 50 %). In the other study, the second cause was cardiac rhythm disturbances caused by methylidigoxin, while in our study the second cause was

warfarine overdose, indicating that digitalis was commonly used 20 years ago. An increasing number of elderly patients are prescribed warfarine today, notably for chronic atrial fibrillation [40].

An Italian study involving 1,756 elderly patients admitted to a geriatric unit showed that 5.8 % of patients had an ADR-related hospitalization. Gastrointestinal disorders, platelet, bleeding, and clotting disorders and cardiovascular disorders were the most frequent ADRs in this study, which is in concordance with our results [41]. Similar results in our study and in studies from other European countries show that we share the same consequences of adverse drugs effects in our elderly patients.

Geriatrics is not recognized as a separate medical specialty in Croatia, nor does a separate geriatric ward exist in our hospitals. This study evaluated patients admitted to the Department of Internal Medicine, and drugs causing ADR-related hospital admissions differ when compared to drugs responsible for admissions to geriatric wards (e.g., side effects of psychotropic drugs are often involved in such cases). Although 53.5 % of the patients were taking at least one ATC class N drug (nervous system), we didn't detect any CNS adverse effects as a cause of admission (e.g., falls or syncope), as those patients would be admitted to a neurology or psychiatry ward instead.

In our study, patients taking PIMs were taking significantly higher numbers of drugs ( $6.3 \pm 2.7$  vs.  $4.5 \pm 2.8$ ), confirming an increased risk for PIMs in patients with polypharmacy. Similar to other studies, a significant number of elderly patients were taking benzodiazepines (31.7 %) or NSAIDs (22.7 %).

The average number of drugs taken by the patients was high both before admission and during hospital stay. This result is also similar to other studies showing polypharmacy in outpatient and inpatient elderly population [42–44]. Most authors agree, however, that we can't define polypharmacy simply as prescribing more than five or nine drugs, but instead, as prescribing "at least one potentially inappropriate drug", because in patients with several chronic conditions the underuse of drugs should also be avoided.

We plan to further test this tool against other similar and widely used tools, such as STOP/START and the Priscus list, in both ambulatory and clinical settings [45–47].

## Conclusion

Eleven percent of the study population was acutely hospitalized due to probable ADRs. In this population, the new Croatian tool detected a high number of patients taking PIMs and/or having potentially important drug-drug interactions. The number of detected PIMs was lower compared to the 2012 Beers list.

The tool revealed almost half of the drugs contributing to ADR-associated admission, as well as three-quarters of drugs causing admission due to GI bleeding. We expect this tool to be useful in the evaluation of prescription patterns in the elderly inpatient and outpatient population, and will continue to test the tool in various settings, comparing it to other explicit tools.

**Conflict of interest** The authors declare that they have no conflicts of interest.

## References

1. Chrischilles EA, Foley DJ, Wallace RB, Lemke JH, Semla TP, Hanlon JT (1992) Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly. *J Gerontol* 47(5):M137–M144
2. Barry M (2002) Drug expenditure in Ireland 1991–2001. *Ir Med J* 95(10):294–295
3. Mannesse CK, Derkx FH, de Ridder MA, Man in't Veld AJ, van der Cammen TJ (2000) Contribution of adverse drug reactions to hospital admission of older patients. *Age Ageing* 29(1):35–39
4. Simonson W, Feinberg JL (2005) Medication-related problems in the elderly: defining the issues and identifying solutions. *Drugs Aging* 22(7):559–569
5. Hohl CM, Dankoff J, Colacone A, Afilalo M (2001) Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. *Ann Emerg Med* 38(6):666–671
6. Veehof LJ, Stewart RE, Meyboom-de Jong B, Haaijer-Ruskamp FM (1999) Adverse drug reactions and polypharmacy in the elderly in general practice. *Eur J Clin Pharmacol* 55(7):533–536
7. Routledge PA, O'Mahony MS, Woodhouse KW (2004) Adverse drug reactions in elderly patients. *Br J Clin Pharmacol* 57(2):121–126
8. Gallagher P, Barry P, O'Mahony D (2007) Inappropriate prescribing in the elderly. *J Clin Pharm Ther* 32(2):113–121
9. Hamilton HJ, Gallagher PF, O'Mahony D (2009) Inappropriate prescribing and adverse drug events in older people. *BMC Geriatr* 9:5
10. Laroche ML, Charnes JP, Bouthier F, Merle L (2009) Inappropriate medications in the elderly. *Clin Pharmacol Ther* 85(1):94–97
11. Passarelli MC, Jacob-Filho W, Figueras A (2005) Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. *Drugs Aging* 22(9):767–777
12. Page RL 2nd, Linnebur SA, Bryant LL, Ruscini JM (2010) Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. *Clin Interv Aging* 5:75–87
13. Beers MH, Ouslander JG, Rollinger I, Reuben DB, Brooks J, Beck JC (1991) Explicit criteria for determining inappropriate medication use in nursing home residents. *Arch Intern Med* 151:1825–1832
14. Beers MH (1997) Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. *Arch Intern Med* 157(14):1531–1536
15. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH (2003) Updating the beers criteria. *Arch Intern Med* 163(22):2716–2724
16. American Geriatrics Society 2012 Beers criteria update expert panel (2012) American Geriatrics Society updated Beers criteria for



- potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 60(4):616–631
17. Marcum ZA, Hanlon JT (2012) Commentary on the new American geriatric society beers criteria for potentially inappropriate medication use in older adults. *Am J Geriatr Pharmacother* 10(2):151–159
  18. Mimica Matanović S, Vlahovic-Palcevski V (2012) Potentially inappropriate medications in the elderly: a comprehensive protocol. *Eur J Clin Pharmacol* 68(8):1123–1138
  19. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC (1997) Defining inappropriate practice in prescribing for elderly people: a national consensus panel. *CMAJ* 156(3):385–391
  20. Laroche ML, Charnes JP, Merie L (2007) Potentially inappropriate medications in the elderly. A French consensus panel list. *Eur J Clin Pharmacol* 63(8):725–731
  21. Lindblad CI, Hanlon JT, Gross CR, Sloane RJ, Pieper CF, Hajjar ER et al (2006) Clinically important drug-disease interactions and their prevalence in older adults. Consensus statement. *Clin Ther* 28(8):1133–1143
  22. Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC et al (2004) Identification of serious drug-drug interactions: results of partnership to prevent drug-drug interactions. *J Am Pharm Assoc* 44(2):142–151
  23. Hanlon JT, Schmader ES (2005) Editorial. Drug-drug interactions in older adults—which ones matter? *Am J Geriatr Pharmacother* 3(2):61–63
  24. Naranjo et al (1981) A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 30:239–245
  25. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 40(5):373–383
  26. Graf J (2010) Analgesic use in the elderly: the “pain” and simple truth: comment on “The comparative safety of analgesics in older adults with arthritis”. *Arch Intern Med* 170(22):1976–1978
  27. Pickering G (2012) Analgesic use in the older person. *Curr Opin Support Palliat Care* 6(2):207–212
  28. Lanas A (2005) Gastrointestinal injury from NSAID therapy. How to reduce the risk of complications. *Postgrad Med* 117(6):23–28, 31
  29. Scheiman JM (2008) Prevention of NSAID-Induced Ulcers. *Curr Treat Options Gastroenterol* 11(2):125–134
  30. Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M (2002) Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. *Arthritis Rheum* 46(8):2195–2200
  31. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ* 342:c7086
  32. European Medicines Agency. European Medicines Agency finalises review of recent published data on cardiovascular safety of NSAIDs. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Press\\_release/2012/10/WC500134090.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/10/WC500134090.pdf). Accessed October 10th 2013
  33. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons (2009) Pharmacological management of persistent pain in older persons. *J Am Geriatr Soc* 57(8):1331–1346
  34. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. *BMJ* 329(7456):15–19
  35. van der Hooft CS, Dieleman JP, Siemes C, Aarnoudse AJ, Verhamme KM, Stricker BH (2008) Adverse drug reaction-related hospitalisations: a population-based cohort study. *Pharmacoepidemiol. Drug Saf* 17(4):365–371
  36. Schneeweiss S, Hasford J, Göttler M, Hoffmann A, Riethling AK, Avorn J (2002) Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. *Eur J Clin Pharmacol* 58(4):285–291
  37. Pouyanne P, Haramburu F, Imbs JL, Bégaud B (2000) Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance centres. *BMJ* 320(7241):1036
  38. Sinha U, Raha S, Wilkins E (2000) Adverse drug reactions and hospital admission of older patients. *Age Ageing* 29(6):551–552
  39. Helldén A, Bergman U, von Euler M, Hentschke M, Odar-Cederlöf I, Ohlén G (2002) Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department: a retrospective study. *Drugs Aging* 26(7):595–606
  40. Huic M, Macolic V, Vrhovac B, Francetic I, Bakran I, Giljanovic S (1994) Adverse drug reactions resulting in hospital admission. *Int J Clin Pharmacol Ther* 32(12):675–682
  41. Onder G, Pedone C, Landi F, Cesari M, Della Vedova C, Bernabei R (2002) Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). *J Am Geriatr Soc* 50(12):1962–1968
  42. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ (2006) Polypharmacy and prescribing quality in older people. *J Am Geriatr Soc* 54(10):1516–1523
  43. Hajjar ER, Cafiero AC, Hanlon JT (2007) Polypharmacy in elderly patients. *Am J Geriatr Pharmacother* 5(4):345–351
  44. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN (2008) Polypharmacy: misleading, but manageable. *Clin Interv Aging* 3(2):383–389
  45. Barry PJ, Gallagher P, Ryan C, O’Mahony D (2007) START (screening tool to alert doctors to the right treatment)—an evidence-based screening tool to detect prescribing omissions in elderly patients. *Age Ageing* 36(6):632–638
  46. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D (2008) STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. *Int J Clin Pharmacol Ther* 46(2):72–83
  47. Holt S, Schmiedl S, Thümann PA (2010) Potentially inappropriate medications in the elderly: the PRISCUS list. *Dtsch Arzteblatt Int* 107(31–32):543–551